Who are CHF6001 DPI's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Olodaterol-Tiotropium, Tolterodine 6, umeclidinium bromide and vilanterol trifenatate, Solifenacin with vaginal estrogen cream, Atimos®, Vilanterol and Umeclidinium Bromide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chf6001-dpi.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

CHF6001 DPI — Competitive Intelligence Brief

CHF6001 DPI (CHF6001 DPI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting muscarinic antagonist. Area: Respiratory.

phase 2 Long-acting muscarinic antagonist M3 muscarinic receptor Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

CHF6001 DPI (CHF6001 DPI) — Chiesi Farmaceutici S.p.A.. CHF6001 DPI is a dry powder inhaler formulation of a long-acting muscarinic antagonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CHF6001 DPI TARGET	CHF6001 DPI	Chiesi Farmaceutici S.p.A.	phase 2	Long-acting muscarinic antagonist	M3 muscarinic receptor
Olodaterol-Tiotropium	Olodaterol-Tiotropium	Fraunhofer-Institute of Toxicology and Experimental Medicine	marketed	Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination)	Beta-2 adrenergic receptor; M3 muscarinic receptor
Tolterodine 6	Tolterodine 6	KYU-SUNG LEE	marketed	Muscarinic receptor antagonist	M2 and M3 muscarinic receptors
umeclidinium bromide and vilanterol trifenatate	umeclidinium bromide and vilanterol trifenatate	Chiesi Farmaceutici S.p.A.	marketed	Long-acting muscarinic antagonist / Long-acting beta-2 agonist combination (LAMA/LABA)	M3 muscarinic receptor and beta-2 adrenergic receptor
Solifenacin with vaginal estrogen cream	Solifenacin with vaginal estrogen cream	Mackay Memorial Hospital	marketed	Anticholinergic agent (solifenacin) + topical estrogen (vaginal cream)	M3 muscarinic receptor (solifenacin); estrogen receptor (vaginal estrogen)
Atimos®	Atimos®	Chiesi Farmaceutici S.p.A.	marketed	Long-acting muscarinic antagonist (LAMA)	M3 muscarinic receptor
Vilanterol and Umeclidinium Bromide	Vilanterol and Umeclidinium Bromide	Samsung Medical Center	marketed	Long-acting beta-2 agonist / Long-acting muscarinic antagonist combination (LABA/LAMA)	Beta-2 adrenergic receptor; M3 muscarinic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting muscarinic antagonist class)

Chiesi Farmaceutici S.p.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CHF6001 DPI — Competitive Intelligence Brief. https://druglandscape.com/ci/chf6001-dpi. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab